AtomVie Global Radiopharma Celebrates the Grand Opening of its New State-of-the-Art Radiopharmaceutical Manufacturing Facility in Hamilton, Ontario

In September 2026, AtomVie Global Radiopharma (AtomVie), a leading global Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, celebrated the Grand Opening of its new purpose-built, state-of-the-art manufacturing facility at 10 Aeropark Boulevard in Hamilton, Ontario. This milestone marks a defining moment in AtomVie's evolution that transforms clinical success into life-changing precision therapies for patients worldwide.

Representing an investment of more than $160 million, the 72,300-square-foot facility is the largest single-site CDMO facility in North America for radiopharmaceutical development to date, and features low-to-high throughput production, delivering more than a tenfold increase in AtomVie's manufacturing capacity. Purpose-built for lifecycle growth, the facility also enables seamless progression from early development to commercial manufacturing of radiopharmaceuticals, with customizable space dedicated to clients' future needs as well.

AtomVie's new facility inauguration further highlights the discipline and dedication of the AtomVie team and the confidence of the partners who have supported our growth. This facility continues AtomVie's status as a leading radiopharmaceutical CDMO, now built at commercial scale to serve partners with the reliability the field requires.

Impact on the Healthcare Market

Built on more than a decade of experience and renowned technical expertise in process and analytical method development, the company has supported over 70 clinical development and technology transfer programs, manufactured more than 1,000 cGMP batches, and delivered over 4,400 cGMP doses to patients across 28 countries and six continents with a delivery success rate of over 99%. With its new facility, AtomVie is well-positioned to scale production with its partners from clinical development to commercial manufacturing.

The Grand Opening celebration also welcomed government representatives, clients, partners, and members of the radiopharmaceutical community for facility tours and a firsthand view of how AtomVie's expertise is helping deliver the next generation of precision cancer therapies to patients worldwide.

Impact on the Radiopharmaceuticals Market

The global radiopharmaceuticals market size is estimated at USD 7.51 billion in 2025 and predicted to increase from USD 8.28 billion in 2026 to approximately USD 15.21 billion by 2035, representing a CAGR of 7.31% from 2026 to 2035.

According to Precedence Research, the radiopharmaceuticals domain is a dynamic sector that has witnessed significant expansion owing to its pivotal role in healthcare. While dealing with regulatory hurdles and logistical challenges, it presents substantial business opportunities for enterprises in research and innovation, further driven by the booming demand for personalized medicine and the escalating prevalence of chronic diseases. The global radiopharmaceuticals market has expanded owing to breakthroughs in healthcare technology, an increasing prevalence of chronic illnesses, and a burgeoning elderly demographic. It plays a pivotal role in personalized medicine and the advancement of innovative medical therapeutics.

The global radiopharmaceuticals market has experienced robust growth, underpinned by advancements in healthcare technology, the rising prevalence of chronic illnesses, and the burgeoning elderly population. A primary factor that is propelling the radiopharmaceuticals market is the rising field of personalized medicine. Radiopharmaceuticals play a pivotal role in customizing medical treatments for individual patients and enhancing therapeutic outcomes. 

Impact on the Radiopharmaceutical CDMO Market

The global radiopharmaceutical CDMO market size accounted for USD 3.24 billion in 2025 and is predicted to increase from USD 3.57 billion in 2026 to approximately USD 8.50 billion by 2035, expanding at a CAGR of 10.12% from 2026 to 2035.

According to Precedence Research, the market is growing steadily, driven by rising nuclear medicine demand, oncology-focused innovation, regulatory outsourcing, and expansion of personalized radiotherapies. The growth of the radiopharmaceutical CDMO market is primarily driven by an increasing utilization of nuclear medicine across oncology, cardiology, and neurology and a growing pipeline of targeted radiotherapies for these indications.

The stringent nature of good manufacturing practices (GMP), Radiation Safety, and Pharmacovigilance enforced by regulatory agencies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) also causes pharmaceutical companies to partner exclusively with CDMOs that comply, as evidenced by their proven records of regulatory inspections. National healthcare programs supporting the establishment of domestic radiopharmaceutical production initiatives have created opportunities for the establishment of local CDMO radiopharmaceutical production facilities, providing the added benefit of reducing the risks associated with the transportation of radioactive products over international borders and losses due to the radioactive decay of product.

Expert Opinion

"This Grand Opening represents the next chapter of AtomVie's journey and a proud milestone for Canadian innovation in nuclear medicine," said Bruno Paquin, Chief Executive Officer of AtomVie. "Our new purpose-built facility amplifies a proven track record of reliable global delivery and deep scientific expertise, enabling us to support the development and commercialization of our partners' pipelines. Above all, it advances our purpose of transforming patients' lives by delivering high-quality radiopharmaceuticals to those who need them, all around the world."